Get the Stockscreener App
106.45
1.34%
1.41
After Hours:
106.20
-0.25
-0.23%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $106.45, with a volume of 5.34M.
It is up +1.34% in the last 24 hours and up +6.03% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$105.04
Open:
$105.365
24h Volume:
5.34M
Relative Volume:
0.38
Market Cap:
$264.21B
Revenue:
$63.90B
Net Income/Loss:
$19.05B
P/E Ratio:
14.08
EPS:
7.5596
Net Cash Flow:
$13.05B
1W Performance:
+7.33%
1M Performance:
+6.03%
6M Performance:
+32.53%
1Y Performance:
+7.04%
1-Day Range:
$105.28
$106.95
1-Week Range:
$98.86
$106.95
52-Week Range:
$73.31
$106.95
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
106.45 | 260.71B | 63.90B | 19.05B | 13.05B | 7.5596 |
|
LLY
Lilly Eli Co
|
1,076.98 | 959.14B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
207.78 | 495.78B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.89 | 404.36B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
138.88 | 266.96B | 54.45B | 14.42B | 17.15B | 7.333 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
Merck & Co. (MRK) Enters 2026 in the Spotlight: BMO Upgrade to $130, FDA Fast-Track Vouchers and TrumpRx Pricing Deal Reframe the Post-Keytruda Story - ts2.tech
Merck (MRK) Stock News on Dec. 25, 2025: BMO Lifts Target to $130 as FDA Fast-Track Vouchers and Keytruda Data Fuel Momentum - ts2.tech
Bar Harbor Wealth Management Buys 14,147 Shares of Merck & Co., Inc. $MRK - MarketBeat
A Tax Auditor's Secret to Building a $22 Million Fortune - The Motley Fool
Merck & Co., Inc. (NYSE:MRK) Sets New 12-Month HighWhat's Next? - MarketBeat
Vontobel Holding Ltd. Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Hanson & Doremus Investment Management Lowers Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Swedbank AB Grows Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Farther Finance Advisors LLC - MarketBeat
Merck & Co., Inc (NYSE:MRK) S&P 500 Companies Biotech Footprint - Kalkine Media
Check Out What Whales Are Doing With MRK - Benzinga
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It? - Finviz
Yousif Capital Management LLC Lowers Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Matrix Trust Co - MarketBeat
HBK Sorce Advisory LLC Acquires 16,271 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by OFI Invest Asset Management - MarketBeat
Cliftonlarsonallen Wealth Advisors LLC Buys 13,414 Shares of Merck & Co., Inc. $MRK - MarketBeat
"Merck (MRK) is an Inexpensive Stock," Says Jim Cramer - Finviz
“Merck (MRK) is an Inexpensive Stock,” Says Jim Cramer - Yahoo Finance
Brighton Jones LLC Buys 20,086 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Position Lessened by Baldwin Wealth Partners LLC MA - MarketBeat
Merck (MRK) Stock: What to Know Before the Market Opens on Dec. 22, 2025 - ts2.tech
Lineweaver Wealth Advisors LLC Has $3.18 Million Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Viking Fund Management LLC Purchases 19,000 Shares of Merck & Co., Inc. $MRK - MarketBeat
Fluent Financial LLC Buys New Holdings in Merck & Co., Inc. $MRK - MarketBeat
Foster Victor Wealth Advisors LLC Grows Position in Merck & Co., Inc. $MRK - MarketBeat
Douglas Lane & Associates LLC Has $45.27 Million Stock Position in Merck & Co., Inc. $MRK - MarketBeat
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans - Business Wire
Rahway-Based Merck & Co., Inc. Recognized at 46th Annual Edison Patent Awards - TAPinto
Voya Investment Management LLC Has $57.55 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Perpetual Ltd - MarketBeat
Secure Asset Management LLC Lowers Stake in Merck & Co., Inc. $MRK - MarketBeat
Cyndeo Wealth Partners LLC Has $10.11 Million Position in Merck & Co., Inc. $MRK - MarketBeat
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal - Benzinga
Merck (MRK) Stock After Hours on Dec. 19, 2025: Trump Drug-Pricing Deal, FDA Fast-Track Vouchers, and What to Watch Before Markets Reopen - ts2.tech
Top Research Reports for NVIDIA, Netflix & Merck - TradingView — Track All Markets
US FDA grants priority vouchers to Merck's cholesterol pill, cancer therapy - Reuters
Patient deaths prompt halt in Merck-Daiichi phase III in lung cancer - BioWorld MedTech
Better Buy in 2026: Pfizer or Merck? - Finviz
Merck & Co Inc (MRK) Stock Price, Trades & News - GuruFocus
Merck (MRK) Stock News and Forecasts for Dec. 19, 2025: Drug-Pricing Deals, FDA Fast-Track Catalysts, and Wall Street Targets - ts2.tech
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Benzinga
Merck Is Partnering With America’s Largest HBCU To Launch a Collaborative Biotechnology Learning Center - CSRwire
Merck (MRK)'s CEO Has a "Better Hand," Says Jim Cramer - Finviz
Merck (MRK)’s CEO Has a “Better Hand,” Says Jim Cramer - Insider Monkey
Trump to announce new deals to lower drug prices, White House says - Reuters
Merck & Co., Inc. $MRK Stock Holdings Boosted by Talbot Financial LLC - MarketBeat
Merck & Co., Inc. : Technically solid - marketscreener.com
Merck's Deep Pipeline And Cash Flow Strength Support The Bull Case - Seeking Alpha
Merck & Co., Inc. (NYSE:MRK) Stock Price Up 1.6% Following Analyst Upgrade - MarketBeat
Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025) - ts2.tech
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.18%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):